Biotech Values

[stockbettor]

another entrant in the HCV treatment arena

In my weekly review of the new clinical trial postings at clinical trials.gov, I came across a a new P2 HCV trial initiated by a private company, Conatus Pharma, for its MMP inhibitor CTS-1027. Conatus has also just completed another P2 trial for this compound and will presumably report results at some point this year. Links to these trials and to the conatus website appear below.

Although I have no great interest in HCV treatments at this moment (too much competition IMO -- but speaking of moments, thanks Dew and all others, for your MNTA coverage), it is a topic of many posts here, and I have not seen this one mentioned before.

http://www.clinicaltrials.gov/ct2/results?term=Conatus

http://conatuspharma.com/products/